Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients

Category Primary study
Web pagePress release - PR Newswire - Dec 15, 2021, 08:00 ET
Year 2021

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information
This article has no abstract
Epistemonikos ID: e0aa4d650e3360359f16c7056df899c310ae0a32
First added on: Jan 04, 2022